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ABSTRACT
The voltage-gated potassium channel Kv1.3 (KCNA3) is expressed by a subset 
of chronically activated memory T cells and plays an important role in their activation 
and proliferation. Here, we show that primary malignant T cells isolated from patients 
with Sézary syndrome (SS) express Kv1.3 and are sensitive to potent Kv1.3 inhibitors 
ShK and Vm24, but not sensitive to a less potent inhibitor [N17A/F32T]-AnTx. Kv1.3 
blockade inhibits CD3/CD28-induced proliferation and IL-9 expression by SS cells in a 
concentration-dependent manner. In parallel, CD3/CD28-mediated CD25 induction is 
inhibited, whereas Kv1.3 blockade has no effect on apoptosis or cell death as judged by 
Annexin V and PI staining. In conclusion, we provide the first evidence that malignant 
T cells in SS express functional Kv1.3 channels and that Kv1.3 blockade inhibits 
activation-induced proliferation as well as cytokine and cytokine receptor expression 
in malignant T cells, suggesting that Kv1.3 is a potential target for therapy in SS.
INTRODUCTION
Sézary syndrome (SS) is an aggressive leukemic 
form of cutaneous T-cell lymphoma (CTCL), which 
constitutes a heterogeneous group of extranodal non-
Hodgkin lymphomas [1]. SS typically manifests as 
erythroderma and leukemic peripheral blood involvement 
by atypical malignant T cells named Sézary cells [2, 3]. SS 
patients experience heavy suffering from severe pruritus, 
desquamation and accompanying infectious complications 
[4]. The etiology is unknown, and genetic, epigenetic, and 
environmental factors have all been implicated in CTCL. 
Notably, a recent study on CTCL in a Danish cohort of 
twins showed no evidence for heredity playing a role in 
CTCL [5]. In parallel, an increasing body of evidence 
suggests that environmental factors may have both an 
etiological and a pathogenic role in CTCL [6–9]. Indeed, 
eradication of skin colonization by staphylococcus 
aureus through aggressive treatment with antibiotics is 
associated with a decrease in the fraction of malignant T 
cells in skin lesions [10] and staphylococcal alpha-toxin 
induces an increased ration between malignant and non-
malignant T cells [11]. Importantly, the pathogenesis of 
CTCL including SS is closely associated with chronic 
inflammation and aberrant activation of nuclear factor-
κB (NF-κB) pathway, nuclear factor of activated T cells 
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(NFAT) pathway, and Janus kinase / signal transducer of 
activation (Jak/STAT) pathway in lesional skin and blood 
[12–15]. Inflammatory macrophages as well as dendritic 
cells are abundant in the CTCL tumor microenvironment 
[16, 17]. Recent genomic studies have reported activating 
mutations in genes such as PLCG1 promoting Ca2+/
Calcineurin-NFAT signaling, leading to malignant 
proliferation in a fraction of CTCL patients [18]. However, 
the overall low recurrence of pathogenic small-scale 
mutations suggests that these are not the primary drivers 
of the disease. Notably, a recent study of single-cell 
heterogeneity showed a high degree of heterogeneity when 
comparing malignant T cells in different SS patients and 
even a considerable heterogeneity within the malignant 
T cell population in each individual patient [19, 20] 
suggesting that genetic instability may play a key role in 
CTCL. MicroRNAs are also important in the pathogenesis 
of CTCL, for some MicroRNAs (e.g., miR-21, miR-
22, miR-155) have been reported to target cell-cycle 
regulators, signaling molecules and tumor suppressors, 
leading to enhanced proliferation, cytokine release, and 
resistance to apoptosis in malignant T cells [21–25]. 
Interestingly, loss of regulatory control through deletion, 
epigenetic silencing, or functional deviation of Jak/STAT 
signaling inhibitors such as SOCS1, SOCS3, SHP-1, 
and HNRNPK also appears to be implicated in aberrant 
cytokine signaling [26–30] indicating that a dynamic, 
multifactorial interplay between genetic, epigenetic and 
environmental triggers drive disease progression in SS and 
other variants of CTCL.
Current therapeutic strategies for SS involve 
multidisciplinary combinations of skin directed therapies 
and systemic chemotherapy, as well as immune-modulators 
(e.g., Interferon α, Bexarotene) and histone deacetylase 
inhibitors (HDACi, e.g., Vorinostat, Romidepsin). In 
recent years targeted therapies are emerging and a number 
of monoclonal antibodies have shown various efficacy 
in SS [31]. For instance, Mogamulizumab targeting C-C 
chemokine receptor 4 (CCR4) has been approved in 
2018 for clinical treatment of SS [32, 33]. Alemtuzumab 
against CD52 gained considerable efficacy [34, 35], and 
Pembrolizumab against programmed cell death protein-1 
(PD-1) showed activity among SS patients in clinical 
trials [36, 37]. Brentuximab vedotin as an antibody-drug 
conjugate targeting CD30 also demonstrated encouraging 
results in CTCL phase II/III trials [38, 39]. In addition, 
a newly developed oligonucleotide inhibitor of miR-155 
named Cobomarsen is being evaluated in a phase II trial 
for CTCL [40]. However, despite all these therapeutic 
options, the prognosis of SS remains poor, and novel 
therapeutics are highly needed [4, 41].
The Kv1.3 ion channel was discovered on 
T lymphocytes over three decades ago [42]. It is 
a voltage-gated potassium channel residing in the 
plasma membrane that plays an important role in T cell 
activation by regulating membrane potential and calcium 
signaling. Kv1.3 channel-mediated K+ efflux maintains 
a negative membrane potential during T cell activation 
providing a driving force for calcium influx and a high 
concentration of cytoplasmic calcium (~ 1 μM) [43, 44]. 
The elevated cytosolic calcium following T cell receptor 
stimulation activates the phosphatase calcineurin that in 
turn dephosphorylates NFAT. Once dephosphorylated, 
NFAT translocates to the nucleus and initiates gene 
transcription, cytokine secretion, and T cell proliferation 
[45, 46]. Blockade of Kv1.3 influences Ca2+ homeostasis 
and inhibits T cell activation and proliferation. Kv1.3 
channels have therefore been proposed to be a promising 
therapeutic target [45, 47]. In past years, Kv1.3 has been 
intensively investigated which has provided a series of 
encouraging results. For instance, in many autoimmune 
diseases, disease-associated autoreactive cells are found 
having high expression of Kv1.3 protein in the plasma 
membrane including multiple sclerosis [48], rheumatoid 
arthritis [49], psoriasis [50], and type-1 diabetes mellitus 
[49]. Moreover, selective Kv1.3 inhibitors have shown 
efficacy in preclinical animal models [48–50], and one 
inhibitor, Dalazatide, is now in clinical trials for psoriasis 
[51], suggesting that Kv1.3 may indeed be a promising 
therapeutic target in chronically activated T-cell disorders.
Malignant T cells in SS derive from chronically 
activated T memory cells [52]. Yet, it has to date not been 
investigated if malignant SS cells express Kv1.3. In this 
study, we explored the expression and possible functions 
of Kv1.3 in SS. We demonstrate that Kv1.3 is expressed 
on primary malignant cells of SS patients, and that Kv1.3 
blockade inhibits malignant cell proliferation and cytokine 
signaling, without inducing apoptosis.
RESULTS
Kv1.3 is expressed by ex vivo isolated malignant 
cells from SS patients
Kv1.3 has been reported to be highly expressed in 
many chronically activated T-cell diseases [48–50]. Yet, no 
studies have investigated the expression of Kv1.3 in SS. 
Accordingly we obtained peripheral blood mononuclear 
cells (PBMCs) from six SS patients and analyzed Kv1.3 
expression using flow cytometry. Malignant cells were 
defined as CD26- within the CD3+CD4+ T cell population 
(Figure 1A). As shown in Figure 1B, Kv1.3 protein was 
expressed on the cell surface of malignant T cells from all 
six SS patients, although at varying levels.
Kv1.3 blockade inhibits activation-induced 
proliferation of malignant T cells from SS 
patients
Since Kv1.3 channels showed to be expressed by 
malignant T cells from SS patients, we next aimed to 
determine whether Kv1.3 augments cell proliferation. We 
Oncotarget4896www.oncotarget.com
used three well characterized Kv1.3 inhibitors with varied 
potency: two potent ones called ShK and Vm24, and a 
150 times less potent one called [N17A/F32T]-AnTx, see 
Supplementary Table 1 [53–55]. We treated PBMCs from 
SS patients with 10-fold increasing concentrations of ShK 
(0, 10, 100 and 1000 nM), with or without anti-CD3/CD28 
beads for 72 hours and measured the incorporation of 
3H-thymidine during the last 24 hours of culture. While no 
3H-thymidine incorporation was observed in the absence 
of bead stimulation, the 3H-thymidine incorporation 
of SS cells stimulated with anti-CD3/CD28 beads was 
inhibited in a dose-dependent manner by the potent Kv1.3 
inhibitors, ShK and Vm24, suggesting that blockade of 
Kv1.3 inhibits the proliferation of SS cells (Figure 2). 
Likewise, ShK inhibited activation induced proliferation 
in another three patients (Figure 3, left), whereas [N17A/
F32T]-AnTx had little effect (Figure 3).
To elucidate whether the reduction of 3H-thymidine 
incorporation in SS cells was caused by increased cell 
death, we analyzed the proportion of apoptotic and dead 
cells in response to ShK treatment by flow cytometry. 
PBMCs from three SS patients were treated with ShK and 
stained with Annexin V and propidium iodide (PI). As 
shown in Figure 4A and 4B, we observed high viability 
(Annexin V- and PI-) and low apoptosis (Annexin V+) 
in unstimulated malignant T cells from all three patients. 
Following anti-CD3/CD28 stimulation, some degree of 
activation-induced cell death (AICD) was observed in one 
patient (SS8) (Figure 4B, lower part), whereas little AICD 
was observed in the other two patients (Figure 4B, upper 
and middle part). The difference between the patients 
could be explained by the functional heterogeneity 
among SS patients [19]. Regardless, increasing ShK 
concentrations did not increase the proportion of apoptotic 
(Annexin V+) or dead (PI+) cells (Figure 4A and 4B), 
indicating that ShK-mediated blockade of Kv1.3 does 
not induce cell death. This finding is in line with previous 
reports indicating that some Kv1.3 inhibitors, including 
ShK, do not induce apoptosis [56, 57].
To confirm that ShK inhibited the proliferation 
of malignant T cells per se, we further analyzed the 
proliferative response at the single-cell level by measuring 
EdU (5-ethynyl-2′-deoxyuridine) incorporation using flow 
cytometry during the last 24 hours of 72 hour long ShK 
treatment. We found that, in the presence of anti-CD3/
CD28 stimulation, the population of malignant T cells 
that had proliferated (marked by TCRVβ+EdU+) was 
decreased by ShK in a dose-dependent manner (Figure 4C 
and 4D). For patient SS2, CD3 was used as a surrogate 
of TCRVβ8 in the EdU staining and the feasibility was 
confirmed in a different staining showing that 99% 
of CD3+CD4+ cells were TCRVβ8+ (see Figure 5B). 
Collectively, these findings strongly suggest that Kv1.3 
blockade inhibits the proliferation of malignant T cells in 
SS patients.
Kv1.3 blockade inhibits activation-induced 
cytokine and cytokine receptor expression in 
malignant T cells from SS patients
As the T cell receptor (TCR)-mediated increase of 
intracellular free calcium is a key trigger of NFAT activation 
and expression of growth factors such as cytokines in 
healthy T cells [43, 44], we next addressed whether Kv1.3 
blockade inhibited TCR-induced cytokine expression. 
Cytokines have been implicated in the pathogenesis of SS 
Figure 1: Kv1.3 is expressed in malignant cells from SS patients. PBMCs from six SS patients (SS1–SS6) were stained with anti-
Kv1.3, CD3, CD4, CD26 antibodies, and 7-AAD and analyzed by flow cytometry. (A) Representative gating strategy for the identification 
of malignant T cells (CD3+CD4+CD26–). (B) Histograms of Kv1.3 protein expression on the malignant T cell population.
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(reviewed in Ref. [15]) and recently, interleukin 9 (IL-9) 
was shown to promote T cell proliferation in healthy and 
malignant T cells [58]. To determine if Kv1.3 inhibition 
altered the cytokine expression in SS cells, we next 
determined the expression of IL-9 by quantitative PCR 
following treatment with or without 1 µM ShK in the 
presence or absence of anti-CD3/CD28 beads. As shown in 
Figure 5A, anti-CD3/CD28 stimulation strongly increased 
the mRNA expression of IL-9, compared to unstimulated 
cells. Notably, the CD3/CD28-mediated IL-9 induction was 
significantly inhibited by ShK, indicating that Kv1.3 plays 
an important role in TCR-mediated cytokine expression in 
SS T cells. This is consistent with our findings that ShK 
inhibits TCR-driven proliferation.
Figure 2: Kv1.3 inhibitors ShK and Vm24 inhibit activation-induced proliferation of PBMCs from SS patients. PBMCs 
from two SS patients were incubated with Kv1.3 inhibitors, ShK and Vm24, in 10-fold increasing concentrations (0, 10, 100 and 1000 nM) 
for 72 hours, with or without anti-CD3/CD28 beads. 3H-thymidine incorporation of the last 24 hours was measured as counts per minute 
(CPM). Data of two experiments with bead stimulation and one representative experiment without bead stimulation are shown. Error bars 
represent standard deviation (SD) of 3 technical replicates.
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Figure 3: Kv1.3 inhibitor ShK inhibits activation-induced proliferation of PBMCs from SS patients, whereas [N17A/
F32T]-AnTx shows little inhibition. PBMCs from three SS patients were incubated with Kv1.3 inhibitors, ShK and [N17A/F32T]-
AnTx, in 10-fold increasing concentrations (0, 10, 100 and 1000 nM) for 72 hours, with or without anti-CD3/CD28 beads. 3H-thymidine 
incorporation of the last 24 hours was measured as counts per minute (CPM). Data of three experiments with bead stimulation and one 
representative experiment without bead stimulation are shown. Error bars represent standard deviation (SD) of 3 technical replicates.
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The high-affinity IL-2 receptor alpha chain (CD25, 
IL-2Rα) is a direct target of calcium activated NFAT in T 
cells and its aberrant expression has been reported in many 
lymphoid malignancies [59–61]. To determine if blocking 
Kv1.3 affected TCR-induced CD25 expression in malignant 
T cells, we examined CD25 expression on malignant T 
cells from three SS patients. Malignant T cells displayed 
pronounced CD25 expression following stimulation by 
Figure 4: Kv1.3 blockade inhibits activation-induced proliferation of malignant T cells from SS patients. PBMCs from 
three SS patients were incubated with 10-fold increasing concentrations of ShK (0, 10, 100 and 1000 nM) for 72 hours in the presence or 
absence of anti-CD3/CD28 beads. EdU was added during the last 24 hours of culture. Anti-CD3, CD4, TCRVβ, EdU, Annexin V and PI 
were stained followed by flow cytometric analysis. Quantification of viability and representative flow cytometric plots are shown in (A) 
and (B). Quantification of malignant proliferation and representative flow cytometric plots are shown in (C) and (D).
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anti-CD3/CD28 beads, which was partly inhibited by Kv1.3 
blockade (Figure 5B and 5C). Thus, ShK induced a dose-
dependent decrease of CD25 surface expression.
Taken together, we provide the first evidence that 
blocking Kv1.3 inhibits activation-induced expression 
of the cytokine receptor CD25, IL-9, and proliferation of 
malignant T cells.
DISCUSSION
The present study provides the first evidence 
that Kv1.3 potassium channels are expressed and play 
a functional role in SS cells. Primary malignant T cells 
from investigated SS patients displayed a modest surface 
expression of Kv1.3. Blockade of Kv1.3 with the potent 
Figure 5: Kv1.3 blockade inhibits activation-induced cytokine and cytokine receptor expression in malignant T cells 
from SS patients. (A) PBMCs from two SS patients were treated with 1 µM ShK in the presence or absence of anti-CD3/CD28 beads for 
72 hours. IL-9 mRNA expression was analyzed by quantitative PCR, with GAPDH as normalization control. Error bars represent standard 
deviation (SD) of 3 technical replicates. (B and C) PBMCs from three SS patients were incubated with different concentrations of ShK (0, 
10, 100 and 1000 nM) for 72 hours in the presence or absence of anti-CD3/CD28 beads. Anti-CD3, CD4, CD25 and TCRVβ were stained 
followed by flow cytometric analysis. Representative plots of CD25 expression (B) and mean fluorescence intensity (MFI) of CD25 in 
malignant populations (C) are shown.
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Kv1.3 inhibitors ShK and Vm24 inhibited TCR-mediated 
activation and proliferation of malignant T cells from 
SS patients. Notably, we observed some degree of 
heterogeneity in Kv1.3 expression among SS patients 
supporting recent reports on inter-individual heterogeneity 
in SS [19]. However, despite varied Kv1.3 expression, 
the TCR-induced proliferation of malignant T cells was 
suppressed by Kv1.3 blockade in all investigated patients. 
These findings show that Kv1.3 channels were not only 
expressed on the surface, but also functional in SS T cells. 
Interestingly, other studies have shown that malignant 
cells of B and T cell origin also express functional Kv1.3 
channels [62, 63], implying that Kv1.3 expression and 
function is not lost during neoplastic transformation of 
B and T cells. On the contrary, Kv1.3 expression may 
provide a growth advantage to malignant cells. In support 
of this, Kv1.3 blockade inhibits activation-induced 
proliferation of malignant T cells (as shown in Figures 
2–4), and inhibits cell proliferation in hematological 
cancers of B cell origin, as shown by others [62, 63].
It is well established that a key event in TCR-
mediated activation of T cells involves the release 
of calcium from internal stores and an influx of 
extracellular calcium resulting in a steep increase in 
intracellular free calcium, which activates the protein 
phosphatase calcineurin to dephosphorylate and activate 
the transcription factor NFAT. In turn, this triggers 
nuclear translocation of NFAT and transcription of 
genes encoding cytokines and their receptors, eventually 
driving mitogenesis and T cell proliferation [43–46]. 
The mechanism by which Kv1.3 blockade inhibits cell 
proliferation has been elucidated in previous studies 
[44, 45, 48, 64]: Kv1.3 inhibitors including ShK block 
potassium efflux by attaching to and obstructing the 
central pore of Kv1.3 channel, which results in a reduced 
influx of extracellular calcium. Gradually, the reduced 
calcium influx decelerates calcineurin activation and 
NFAT signaling leading to a relative decrease in gene 
transcription, cytokine secretion and cell proliferation. 
In our study, we found that the Kv1.3 blocker ShK 
inhibited anti-CD3-CD28 bead-induced expression of 
the high-affinity IL-2 receptor CD25, transcription of the 
cytokine and malignant growth factor IL-9 [65], and T cell 
proliferation. Our data thus support the hypothesis that 
Kv1.3 channels are expressed and functional in malignant 
T cells.
While Kv1.3 inhibition has been reported to 
induce apoptosis in B-CLL cells [62], we did not 
observe increased apoptosis following Kv1.3 blockade in 
malignant T cells (Figure 4A and 4B), which is consistent 
with previous reports showing that ShK does not induce 
apoptosis in healthy T cells [57].
It is generally believed that SS and other variants 
of CTCL arise from chronically activated T cells as also 
reflected by their memory T cell phenotype [52]. However, 
it is unknown what drives this chronic stimulation of 
malignant T cells. Both endogenous and exogenous 
factors are believed to be involved. For instance, gain-
of-function mutations affect signaling pathways to drive 
T cell activation, and the loss of regulatory control due 
to deletions in SOCS1 or epigenetic silencing of SHP-
1, lower the activation threshold and may drive aberrant 
activation and proliferation [9, 26, 27, 29]. Exogenous 
factors such as bacteria and their toxins may also trigger 
or amplify chronic activation of malignant T cells [7]. 
Notably, malignant T cells induce structural changes in 
the skin, which compromises skin barrier function [66] 
and possibly paves the way for bacterial colonization of 
lesional skin by toxin producing Staphylococcus aureus, 
which is a characteristic feature of SS [67]. Moreover, 
Staphylococcal toxins induce activation of proto-
oncogenes such as STAT3 and a release of inflammatory 
and immune regulatory cytokines [7]. Thus, it is likely 
that multiple factors – endogenous and exogenous – act in 
concert to induce proliferation of malignant T cells. In this 
context, Kv1.3 could be a potential target for therapy. Due 
to the moderate inhibitory effect of ShK on activation and 
proliferation of malignant T cells, Kv1.3 inhibitors may, at 
first glance, not appear as ideal therapeutic candidates for 
mono-therapy of SS. However, as SS patients notoriously 
develop drug resistance, it is feasible that Kv1.3 inhibition 
might have a role in combination-therapy together with 
other drugs targeting different disease mechanisms such 
as resistance to apoptosis. HDAC inhibitors (HDACi), 
such as vorinostat and romidepsin, induce apoptosis in 
SS cells [68, 69], but they may not be able to completely 
eliminate all malignant subpopulations in these patients 
[19], potentially leading to cancer recurrence and 
treatment resistance. Thus, it is likely that multiple drugs 
directed against different targets are needed to obtain 
high treatment efficacy in each individual patient. As 
such, Kv1.3 blockers might have a role in a personalized 
treatment approach to SS. Accordingly, studies are in 
progress to investigate the effect on primary SS cells ex 
vivo by ShK in combination with approved treatments 
such as HDACi, retinoids, and interferon-α.
In conclusion, the present study provides first 
evidence that malignant T cells from SS patients express 
functional Kv1.3 channels, and that Kv1.3 blockade 
inhibits activation induced CD25 and IL-9 expression 
and proliferation of SS cells, suggesting that Kv1.3 is a 
potential therapeutic target in SS.
MATERIALS AND METHODS
Patient cells
In accordance with the Declaration of Helsinki, the 
samples were obtained with written informed consent 
from all patients after approval by the Committee on 
Health Research Ethics. Peripheral blood mononuclear 
cells (PBMCs) were isolated from the blood of Sézary 
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syndrome (SS) patients by density-gradient centrifugation, 
using LymphoPrep and Sepmate-50 tubes (Stem Cell 
Technologies, Cat# 07851 and Cat# 85460, Cambridge, 
UK). Malignant SS T cells typically lack the expression 
of cell surface marker CD26 and express a common 
TCRVβ chain [1]. Accordingly, T cells were identified 
as malignant (TCRVβ+ or CD26–) and non-malignant 
(TCRVβ- or CD26+).
Kv1.3 inhibitors
ShK (a toxin from sea anemone Stichodactyla 
helianthus), Vm24 (a toxin from scorpion Vaejovis 
mexicanus smithi) and [N17A/F32T]-AnTx (a mutant 
toxin from scorpion Anuroctonus phaiodactylus) 
were synthesized and tested by Zealand Pharma A/S 
(Copenhagen, Denmark). A CHO cell line stably 
expressing human Kv1.3 channel (hKv1.3) was purchased 
from Perkin Elmer. hKv1.3 activities in different 
concentrations of Kv1.3 inhibitors were measured using 
the FluxOR Potassium Ion Channel Assay from Invitrogen 
as described by the manufacturer. The flux of thallium 
ions into the cells as a response to Kv1.3 activation was 
quantified using a Fluorometric Imaging Plate Reader 
(FLIPR®) instrument from Molecular Devices, shown in 
Supplementary Table 1.
[Methyl-3H]-thymidine proliferation assay
Assays were performed in RPMI-1640 medium 
containing 2 mM L-glutamine, 0.5 units/mL penicillin, 
0.1 mg/mL streptomycin (Sigma-Aldrich, Darmstadt, 
Germany) and 10% human serum (Bloodbank, 
Rigshospitalet, Denmark).
25,000 PBMCs were seeded per well in 96-well round 
bottom plates in different concentrations of Kv1.3 inhibitors, 
stimulated or non-stimulated with anti-CD3/CD28 beads 
(Cat# 11132D; Thermo Fisher) and incubated for 72 hours. 
3H-thymidine (6.7 Ci; Perkin Elmer, Skovlunde, Denmark) 
was added 24 hours before cells were harvested onto glass 
fiber filter plates (Uni-Filter-96 GF/C; Perkin Elmer) using 
FilterMate cell harvester (Unifilter-96; Perkin Elmer). 
Filter plates were dried over night at room temperature, and 
scintillation fluid was added (MicroScint-O; Perkin Elmer), 
then 3H-thymidine incorporation was measured as counts per 
minute (CPM) in a scintillation counter (TopCount NXT; 
Parkard, Meriden, CT, USA).
Flow cytometry
Antibodies against CD3, CD4, CD25, CD26, 
TCRVβ1, TCRVβ8 and TCRVβ18 as well as Annexin V 
were purchased from BD Biosciences, BioLegend, Miltenyi 
Biotec or Beckman Coulter. Dead cells were excluded using 
propidium iodide (PI). FITC conjugated Kv1.3 antibody 
was purchased from Sigma-Aldrich (Cat# P4247-50UL).
Single cell suspension was assured by filtering 
cells through a 100 µm cell strainer. For all stainings, 
antibodies were diluted in BD Brilliant Stain Buffer 
(Cat# 563794; BD Biosciences) and stained for 30 
minutes at room temperature protected from light. 
For Annexin V staining, surface stained cells were 
resuspended in 50 µl Annexin V binding buffer (Cat# 
556454; BD Biosciences) containing Annexin V and 
PI and incubated at room temperature for 15 minutes 
protected from light followed by addition of 150 µl 
Annexin V binding buffer and analyzed immediately. 
EdU (5-ethynyl-2′-deoxyuridine) incorporation was 
analyzed using the Click-iT® Plus EdU Alexa Fluor® 
488 Flow Cytometry Assay Kit (Cat# C10632; Thermo 
Fisher) according to manufacturer’s instructions. PBMCs 
were seeded 100,000 cells per well in 96-well round-
bottom plates in different concentrations of ShK, with or 
without anti-CD3/CD28 bead stimulation, and incubated 
for 72 hours. EdU was added to the wells 24 hours before 
cells were harvested.
Flow cytometric analysis was conducted on a 5 laser 
BD LSR-Fortessa at the Core Facility for Flow Cytometry 
at the University of Copenhagen. Data were analyzed 
using the FlowJo software (Treestar, Ashland, OR, USA).
RNA purification and quantitative PCR
Total RNA was purified with miRNeasy Mini 
Kit (Cat# 217004; Qiagen), and cDNA was transcribed 
from 450 ng RNA using High-Capacity cDNA Reverse 
Transcription Kit (Cat# 4368813; Applied Biosystems). 
All samples were DNAse treated before cDNA synthesis 
using DNase 1 (Cat# AMPD1-1KT; Sigma-Aldrich). 
Quantitative PCR (qPCR) was performed using Taqman 
Gene Expression assay probes/primers (Thermo Fisher) 
and LightCycler 480 probes master mix. Amplification 
was performed using a LightCycler 480 II (Roche, 
Hvidovre, Denmark). mRNA expression is presented 
as relative quantity to the control determined by ddCt 
method. IL-9 (Cat# Hs00174125-m1) and GAPDH (Cat# 
Hs02786624-g1) probes were purchased from Thermo 
Fisher.
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